Created in 2004 with an innovative technology of tissue detection in CT scan, Intrasense designs, develops and markets Myrian®, a unique, vendor-neutral software suite for the visualization and advanced processing of multimodal medical images such as MRI, CT scans, PET, X-rays, and more. Developed with leading academic and scientific partners, Myrian® combines and uses all of the various medical images to extract information vital to the patient's care, to evaluate treatment efficiency and to assess drug candidates in oncology and other pathologies. With more than 700 client sites around the world, Myrian® has been certified as a "medical device" in over 40 countries including the United States (FDA), Europe (CE) and Asia. Intrasense SA is listed on the Alternext (FR0011179886 - ALINS).The company employs 60 people, including 25 dedicated in R&D.

Key Staff

Stephane Chemouny

Stephane Chemouny, PhD, Male, Chairman and CEO of Intrasense. was trained in Mathematics and Computer Science. After initial experience in Silicon Valley in the mid-nineties, he was awarded a Doctorate from Montpellier (2001) in Diagnostic Imaging of Liver Cancer. His work enabled him to found Intrasense, a benchmark editor of medical imaging software. He specialises in image processing and has co-authored 40 publications on computer science, medical imaging and agronomy. He has won several national and international competitions, plus support from the Ministry for Research and Technology 2003, innovation contests in 2004 and 2007, the 2007 European ICT Award, and the 2009 Ernst & Young Entrepreneur of the Year Award for the Southern Region of France.

Philippe Michelon

Philippe Michelon graduated from Robert Gordon University in the UK with a degree in Applied Physics and has more than 15 years of experience in medical imaging and radiotherapy. Has was a global manager of clinical applications for Kodak Health (now Carestream Health), then managed PACS integration and cardiac applications for Median Technologies. He defines the product plans and new clinical applications in cooperation with clinical partners at Intrasense.